Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430518 | 0.88 | MAOA (0.44) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL5238902 | 0.88 | MAOA (0.48) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL5543767 | 0.76 | CES1 (0.38) | KDM4ECES1CYP2A6ABCB1TDP1 | |
| SCHEMBL569106 | 0.74 | TYMS (0.44) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL192783 | 0.74 | SRD5A1 (0.53) | CA1CA2CA7CA9CES1 | |
| SCHEMBL1339854 | 0.74 | TDP2 (0.47) | KDM4ECES1CYP2A6ABCB1TDP1 | |
| SCHEMBL1340784 | 0.74 | MEN1 (0.45) | KDM4ECES1CYP2A6ABCB1PARP1 | |
| SCHEMBL668042 | 0.74 | MAPT (0.55) | KDM4ECA1CA2CA7CA9 | |
| SCHEMBL16451424 | 0.74 | CES1 (0.46) | CA1CA2CA7CA9CES1 | |
| SCHEMBL19030767 | 0.74 | MEN1 (0.30) | MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820191-B | Diphenylamine compound and preparation method, application and pharmaceutical composition thereof | FUDAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026101924-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025229494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1741693-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | Nagoya Industrial Science Research Institute (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-0357742-B1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES | ROUSSEL-UCLAF (FR) | 1993-06-09 | — | — | EP | disclosed |
| US-5180741-A | Insecticides | ROUSSEL UCLAF (FR) | 1993-01-19 | — | — | US | disclosed |
| EP-0357742-A1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES. | ROUSSEL UCLAF (FR) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989008096-A1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES | ROUSSEL-UCLAF (FR) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | ADH1C, ADH1A, ADH5 | KDM4E 2233/4885CA1 4211/4885CA2 4052/4885 |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | KDM4E 1533/4885CA1 3816/4885CA2 2770/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | KDM4E 1964/4885CA1 4864/4885CA2 4491/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | KDM4E 2825/4885CA1 2449/4885CA2 730/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | KDM4E 1964/4885CA1 4864/4885CA2 4491/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | KDM4E 4812/4885CA1 3214/4885CA2 2881/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | KDM4E 1902/4885CA1 3884/4885CA2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.